Bonus Shares Incoming: Aptus Pharma, Biogen Pharmachem And Dev Labtech Step Up

Record Dates Take Center Stage

Aptus Pharma has fixed May 12, 2026 as the record date for its 3:2 bonus issue, meaning eligible shareholders will receive three bonus shares for every two held. The company’s latest bonus move follows shareholder approval through postal ballot and is designed to reward investors while increasing liquidity.

Biogen Pharmachem’s Smaller But Notable Payout

Biogen Pharmachem Industries has set May 15, 2026 as the record date for its 1:6 bonus issue, giving one extra share for every six held. Shareholders approved the proposal overwhelmingly, alongside an increase in authorized share capital, signalling room for future corporate expansion.

Dev Labtech Venture Joins The List

Dev Labtech Venture is also in the bonus-share spotlight, with a 1:1 issue and a May 15, 2026 record date. In practical terms, investors will receive one additional share for every existing share, effectively doubling their holding count without changing total investment value immediately.

Why Investors Care

Bonus issues do not create instant wealth, but they often improve liquidity, widen retail participation, and signal management confidence. For traders and long-term investors alike, this week’s corporate actions mean attention will likely shift to ex-date timing, price adjustment mechanics, and post-bonus demand trends.

Key Highlights

Aptus Pharma: 3:2 bonus issue, record date May 12, 2026.

Biogen Pharmachem Industries: 1:6 bonus issue, record date May 15, 2026.

Dev Labtech Venture: 1:1 bonus issue, record date May 15, 2026.

All three corporate actions are aimed at rewarding shareholders and improving liquidity.

Sources: Business Today, Choice India, WhalesBook, Scanx, Upstox, Pocketful